Importantly, STAT3 is also revealed here to be a targetable vulnerability that disables the growth of bone metastatic PCa, suggesting that STAT3 inhibitors such S3I-20138, which appears well-tolerated in pre-clinical studies, and have potential in the prostate cancer clinic. This evidence concerns the gene STAT3 and prostate cancer.